N-acetylcysteine as a potential treatment for blood clotting in type-2 diabetes
Author Information
Author(s): Kyle R Gibson, Tim J Winterburn, Fiona Barrett, Sushma Sharma, Sandra M MacRury, Ian L Megson
Primary Institution: University of the Highlands & Islands
Hypothesis
Does N-acetylcysteine inhibit platelet hyperaggregability in blood from patients with type-2 diabetes?
Conclusion
N-acetylcysteine reduces thrombotic risk in type-2 diabetes patients by enhancing platelet antioxidant status.
Supporting Evidence
- N-acetylcysteine increased intraplatelet GSH levels.
- N-acetylcysteine reduced reactive oxygen species generation.
- N-acetylcysteine inhibited thrombin- and ADP-induced platelet aggregation.
Takeaway
N-acetylcysteine can help people with type-2 diabetes by making their blood cells less sticky, which can prevent clots.
Methodology
Blood samples from type-2 diabetes patients were treated with N-acetylcysteine and assessed for platelet aggregation and antioxidant levels.
Limitations
The study was conducted in vitro, and results may not fully translate to in vivo conditions.
Participant Demographics
{"age":"59.2 ± 3.7","gender_ratio":"10 males, 5 females","BMI":"32.2 ± 1.9","HbA1C":"6.5 ± 0.3"}
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website